Pearson ADR

SAN DIEGO , April 9, 2025 /PRNewswire/ -- Pearson (FTSE: PSON.L) and its Pearson VUE business, the global leader in computer-based testing, released their newest Value of IT Certification Candidate Report. This comprehensive study, the ninth in an ongoing series, provides crucial insights into the evolving landscape of IT certification and its impact on professionals and organizations worldwide.» Mehr auf prnewswire.com

New brand identity reflects learning as a core human need, essential for personal happiness and progress LONDON , April 7, 2025 /PRNewswire/ -- Pearson (FTSE: PSON.L), the world's leading learning company, today unveiled a dynamic new brand identity that demonstrates its leadership as a lifelong learning company. More than just a refreshed logo, the rebrand represents a deep understanding of the evolving needs of learners worldwide.» Mehr auf prnewswire.com

MNV-201 is Minovia's second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare Pediatr i c Designation granted MNV-201 is also being studied in a Phase Ib for low-risk Myelodysplastic Syndrome; Preliminary clinical data demonstrate safety and efficacy HAIFA, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd, a clinical stage biopharmaceutical company advancing mitochondrial therapies for primary and secondary mitochondrial diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its second Investigational New Drug (IND) application for MNV-201 , an autologous hematopoietic stem cell product augmented with allogeneic mitochondria . The IND supports the initiation of a Phase I I clinical trial of MNV-201 in pediatric patients with Pearson Syndrome, a primary mitochondrial disease.» Mehr auf globenewswire.com